Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230001/S012

ColoSense

Geneoscopy, Inc. · Decision date Aug 27, 2026

FDA DECISIONP230001/S012

What did the FDA approve?

FDA records P230001/S012 as a supplement to PMA P230001, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Aug 27, 2026.

FDA approval order statement

ColoSense is intended for the qualitative detection of colorectal neoplasia associated RNA markers and for the presence of occult hemoglobin in human stool. ColoSense is a single-site test performed at Geneoscopy, Inc. A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA), or serrated precancerous lesions (SPL) and should be followed by a colonoscopy. ColoSense is indicated as a screening test for adults, 45 years of age or older, who are at typical average-risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Pathology
Decision date
Aug 27, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P230001/S012
Regulatory pathway
PMA supplement
Product code
SBB
Decision code
APPR
Decision date
Aug 27, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, Colorectal Neoplasia, RNA Markers and Hemoglobin detection.

Product code
SBB
FDA device class
3

For the original device and its historical approval scope, see PMA P230001. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230001/S012 received

    Application receipt date recorded by FDA.

  2. P230001/S012 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P230001. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230001

Product / regulatory recordCompanyPathwayDecision dateSource
ColoSenseP230001
Geneoscopy, Inc.PMA approvalMay 3, 2024FDA
ColoSenseP230001/S010
Geneoscopy, Inc.PMA supplementAug 14, 2025FDA
ColoSenseP230001/S009
Geneoscopy, Inc.PMA supplementSep 15, 2025FDA
ColoSenseP230001/S011
Geneoscopy, Inc.PMA supplementOct 24, 2025FDA
ColoSenseP230001/S014
Geneoscopy, Inc.PMA supplementSep 8, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Geneoscopy, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
2220 Welsch Industrial Ct., St. Louis, MO, 63146

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records